Rochester, NY (PRWEB) December 27, 2013
polyDNA has learned that Gilead Sciences’ new drug against hepatitis C “is so effective, Wall Street analysts say, that it’s possible public health officials could begin thinking about eradicating the liver-damaging virus (1).” However, the high cost of the drug, which is reported to be $1,000 per pill and $84,000 for 12 weeks of therapy, is making many people angry. “A San Antonio woman named Margaret Dudley even started an online petition accusing the company of profiteering. ‘This cure is literally being withheld from millions by pharmaceutical giant Gilead Sciences because they are more concerned about profits than human lives (1).’”
Gilead Sciences’ new drug answers a major problem, which is refusing treatment by many HCV patients. A study published on October 31, 2013 in the Journal of Community Health suggested that these patients refused treatment due to their fear of side effects. These side effects include depression, difficulty breathing, swelling in the face, weight loss, cramps, and bleeding gums (2). The result of these refusals is lack of treatment (2).
Just one component of Gilead’s new drug, called Sovaldi, “gets rid of the virus in many patients who were failed by other treatments, and allows many to forego interferon, an infused treatment that causes terrible flu-like symptoms (1).” When put together with the second component, ledipasvir, the drug combo “cures 95% of patients with the genotype-1 version of hepatitis C (1).” In other words, patients can take this drug combo without the usual side-effects.
However, the extremely high cost makes the new HCV drug unaffordable for most patients. As the Forbes article noted, “Drug companies tend to do better in the long run when they can argue they have the ethical high ground, and Gilead lost some of that credibility … (1).”
polyDNA recommends that doctors prescribe a safe, natural HCV remedy to their patients, which most patients can afford. Gene-Eden-VIR has no side effects, according to a post-marketing clinical study published on August 21, 2013 in the journal Pharmacology & Pharmacy (3). As a result, it is more suitable for continuous use, and therefore may be a prime candidate for patients suffering from a chronic Hepatitis C infection.
Gene-Eden-VIR was designed to help the immune system target chronic HCV, or latent Hepatitis C virus. The study reports that Gene-Eden-VIR safely and effectively decreases symptoms in individuals infected with the Hepatitis C virus (HCV) (3).
Study authors wrote that “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (3).”
To view the entire paper on Gene-Eden-VIR, visit http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf
To learn more about Gene-Eden-VIR, visit http://gene-eden-kill-virus.com/HCV.php.
We invite doctors to contact us with their questions at: info(at)buy-gene-eden(dot)com or phone 585-250-9999.
(1) Gilead's $1,000 Pill Could Eradicate Hepatitis C, But Ethical And Financial Challenges Loom. Published on December 19, 2013.
(2) Awareness of Biologically Confirmed HCV Among a Community Residing Sample of Drug Users in Baltimore City. Published on October 31, 2013.
(3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.